Palmitoyl Tetrapeptide-7
Palmitoyl-GQPR (Pal-Gly-Gln-Pro-Arg)
Overview
Palmitoyl Tetrapeptide-7 is a synthetic lipopeptide that works synergistically with Palmitoyl Tripeptide-1 in the widely used Matrixyl 3000 combination. While Palmitoyl Tripeptide-1 stimulates matrix production Palmitoyl Tetrapeptide-7 reduces the inflammatory degradation of that matrix by inhibiting interleukin-6. Together they represent a two-pronged approach to skin aging — building collagen while simultaneously preventing its destruction. Multiple clinical trials have demonstrated the combination's efficacy for wrinkle reduction and skin rejuvenation.
Mechanism of Action
Palmitoyl Tetrapeptide-7 is a fragment of the immunoglobulin G Fc region that acts as an anti-inflammatory signal in skin tissue. Its primary mechanism is inhibition of interleukin-6 (IL-6) — a pro-inflammatory cytokine that activates matrix metalloproteinases (MMPs) which degrade collagen and elastin. By reducing IL-6 production in keratinocytes and fibroblasts Palmitoyl Tetrapeptide-7 reduces MMP activity protecting existing collagen and elastin from degradation. This anti-inflammatory mechanism complements the collagen-stimulating activity of Palmitoyl Tripeptide-1 — one peptide builds collagen while the other prevents its breakdown. The palmitoyl group provides the same lipophilic penetration enhancement as in Palmitoyl Tripeptide-1.
Dosage Information
Typical Dose
2-4% concentration in topical formulation
Frequency
Once or twice daily
Administration
Topical serum or cream
Notes
Most commonly used in the Matrixyl 3000 combination with Palmitoyl Tripeptide-1. Synergistic effects are greater than either peptide alone.
Where does Palmitoyl Tetrapeptide-7 sit?
See how this peptide compares across all 111 peptides in our database.
Evidence Score
0.12
Compound Data
Molecular Formula
C34H62N8O7
Molecular Weight
694.90 g/mol
IUPAC Name
(2S)-2-[[(2S)-1-[(2S)-5-amino-2-[[2-(hexadecanoylamino)acetyl]amino]-5-oxopentanoyl]pyrrolidine-2-carbonyl]amino]-5-(diaminomethylideneamino)pentanoic acid
PubChem CID
10078408Potential Side Effects
Community Experiences
No experiences shared yet. Be the first!
Quick Facts
- Administration
- Topical serum or cream
- Typical Dose
- 2-4% concentration in topical formulation
- Frequency
- Once or twice daily
- References
- 0 curated + 1 from PubMed
- Evidence Score
- 0.1 / 100